Literature DB >> 34961784

Can serum periostin predict bronchopulmonary dysplasia in premature infants?

Hayato Go1, Junya Ono2, Hitoshi Ohto3, Kenneth E Nollet4, Kenichi Sato5, Yohei Kume5, Hajime Maeda5, Mina Chishiki5, Kentaro Haneda5, Hirotaka Ichikawa5, Nozomi Kashiwabara5, Yuji Kanai5, Kei Ogasawara5, Maki Sato5, Koichi Hashimoto5, Satoshi Nunomura6, Kenji Izuhara6, Mitsuaki Hosoya5.   

Abstract

BACKGROUND: Bronchopulmonary dysplasia (BPD) is the most common morbidity complicating preterm birth and affects long-term respiratory outcomes. The objectives of this study were to establish whether serum periostin at birth, day of life (DOL) 28, and corrected 36 weeks' gestational age could be potential biomarkers for BPD.
METHODS: A total of 98 preterm Japanese infants born at <32 weeks and comparing 41 healthy controls born at term, were divided into BPD (n = 44) and non-BPD (n = 54) cohorts. Serum periostin levels were measured using an enzyme-linked immunosorbent assay.
RESULTS: Among 98 preterm infants, the median serum periostin levels at birth were higher with BPD (338.0 ng/mL) than without (275.0 ng/mL, P < 0.001). Multivariate analysis revealed that serum periostin levels at birth were significantly associated with BPD (P = 0.013). Serum periostin levels at birth with moderate/severe BPD (345.0 ng/mL) were significantly higher than those with non-BPD/mild BPD (283.0 ng/mL, P = 0.006).
CONCLUSIONS: Serum periostin levels were significantly correlated with birth weight and gestational age, and serum periostin levels at birth in BPD infants were significantly higher than that in non-BPD infants. IMPACT: This study found higher serum periostin levels at birth in preterm infants subsequently diagnosed with bronchopulmonary dysplasia. It also emerged that serum periostin levels at birth significantly correlated with gestational age and birth weight. The mechanism by which serum periostin is upregulated in BPD infants needs further investigation.
© 2021. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.

Entities:  

Year:  2021        PMID: 34961784     DOI: 10.1038/s41390-021-01912-w

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.953


  34 in total

Review 1.  General and respiratory health outcomes in adult survivors of bronchopulmonary dysplasia: a systematic review.

Authors:  Aisling Gough; Dale Spence; Mark Linden; Henry L Halliday; Lorcan P A McGarvey
Journal:  Chest       Date:  2011-11-23       Impact factor: 9.410

Review 2.  Periostin: An emerging biomarker for allergic diseases.

Authors:  Kenji Izuhara; Satoshi Nunomura; Yasuhiro Nanri; Junya Ono; Masayuki Takai; Atsushi Kawaguchi
Journal:  Allergy       Date:  2019-05-03       Impact factor: 13.146

Review 3.  Chronic lung disease after premature birth.

Authors:  Eugenio Baraldi; Marco Filippone
Journal:  N Engl J Med       Date:  2007-11-08       Impact factor: 91.245

4.  Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias.

Authors:  M Okamoto; T Hoshino; Y Kitasato; Y Sakazaki; T Kawayama; K Fujimoto; K Ohshima; H Shiraishi; M Uchida; J Ono; S Ohta; S Kato; K Izuhara; H Aizawa
Journal:  Eur Respir J       Date:  2010-12-22       Impact factor: 16.671

5.  Impaired lung function and health status in adult survivors of bronchopulmonary dysplasia.

Authors:  Aisling Gough; Mark Linden; Dale Spence; Chris C Patterson; Henry L Halliday; Lorcan P A McGarvey
Journal:  Eur Respir J       Date:  2013-07-30       Impact factor: 16.671

Review 6.  Neurodevelopmental outcome of bronchopulmonary dysplasia.

Authors:  Peter J Anderson; Lex W Doyle
Journal:  Semin Perinatol       Date:  2006-08       Impact factor: 3.300

Review 7.  Bronchopulmonary dysplasia.

Authors:  John P Kinsella; Anne Greenough; Steven H Abman
Journal:  Lancet       Date:  2006-04-29       Impact factor: 79.321

8.  Cross-Talk between Transforming Growth Factor-β and Periostin Can Be Targeted for Pulmonary Fibrosis.

Authors:  Yasuhiro Nanri; Satoshi Nunomura; Yasuhiro Terasaki; Tomohito Yoshihara; Yusuke Hirano; Yasuyuki Yokosaki; Yukie Yamaguchi; Carol Feghali-Bostwick; Keiichi Ajito; Shoichi Murakami; Simon J Conway; Kenji Izuhara
Journal:  Am J Respir Cell Mol Biol       Date:  2020-02       Impact factor: 6.914

Review 9.  Periostin in allergic inflammation.

Authors:  Kenji Izuhara; Kazuhiko Arima; Shoichiro Ohta; Shoichi Suzuki; Masako Inamitsu; Ken-ichi Yamamoto
Journal:  Allergol Int       Date:  2014-03-25       Impact factor: 5.836

10.  Periostin plays a critical role in the cell cycle in lung fibroblasts.

Authors:  Tomohito Yoshihara; Yasuhiro Nanri; Satoshi Nunomura; Yukie Yamaguchi; Carol Feghali-Bostwick; Keiichi Ajito; Shoichi Murakami; Masaaki Mawatari; Kenji Izuhara
Journal:  Respir Res       Date:  2020-01-30
View more
  1 in total

1.  The Patent Ductus Arteriosus in Extremely Preterm Neonates Is More than a Hemodynamic Challenge: New Molecular Insights.

Authors:  Anna Sellmer; Tine Brink Henriksen; Johan Palmfeldt; Bodil Hammer Bech; Julie Astono; Tue Bjerg Bennike; Vibeke Elisabeth Hjortdal
Journal:  Biomolecules       Date:  2022-08-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.